Neurochemical findings in the MPTP model of Parkinson's disease

[1]  R. Elble.  Animal Models of Action Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Beal,et al.  Experimental models of Parkinson's disease , 2001, Nature Reviews Neuroscience.

[3]  F. Weih,et al.  Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. , 2001, Neuroreport.

[4]  B. Ferger,et al.  Neuroprotective effects of (±)‐kavain in the MPTP mouse model of Parkinson's disease , 2001, Synapse.

[5]  G. Petzinger,et al.  The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.

[6]  B. Ferger,et al.  Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease , 2001, Synapse.

[7]  J. Langston,et al.  Increased striatal dopamine turnover following acute administration of rotenone to mice , 2000, Brain Research.

[8]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[9]  K. Mohanakumar,et al.  Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 2000, Brain Research.

[10]  S. Mandel,et al.  MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies , 2000, Journal of Neurology.

[11]  W. Oertel,et al.  The Protective Effects of PBN Against MPTP Toxicity Are Independent of Hydroxyl Radical Trapping , 2000, Pharmacology Biochemistry and Behavior.

[12]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[13]  S. Pennathur,et al.  Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.

[14]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[15]  W. H. Oertel,et al.  Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[16]  Markus Schwaninger,et al.  NF-κB is activated and promotes cell death in focal cerebral ischemia , 1999, Nature Medicine.

[17]  A. Członkowska,et al.  The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.

[18]  C. Carter,et al.  Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.

[19]  Y. Mitsumoto,et al.  Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. , 1998, Biochemical and biophysical research communications.

[20]  I. Nakano,et al.  Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatum , 1998, Neuroscience Letters.

[21]  H. Tanila,et al.  Cognitive Changes in Mice Following Moderate MPTP Exposure , 1998, Brain Research Bulletin.

[22]  E. Bézard,et al.  Effects of Different Schedules of MPTP Administration on Dopaminergic Neurodegeneration in Mice , 1997, Experimental Neurology.

[23]  J. Langston,et al.  MPTP: A Dopaminergic Neurotoxin , 1997 .

[24]  D. D. Di Monte,et al.  Inhibition of Monoamine Oxidase Contributes to the Protective Effect of 7‐Nitroindazole Against MPTP Neurotoxicity , 1997, Journal of neurochemistry.

[25]  E. Bézard,et al.  Kinetics of nigral degeneration in a chronic model of MPTP-treated mice , 1997, Neuroscience Letters.

[26]  H Ujike,et al.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Gainetdinov,et al.  Dopamine Transporter Is Required for In Vivo MPTP Neurotoxicity: Evidence from Mice Lacking the Transporter , 1997, Journal of neurochemistry.

[28]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[29]  A. Kupsch,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level , 1996, Brain Research.

[30]  M. Memo,et al.  Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-κB Activation , 1996, Science.

[31]  M. Beal,et al.  Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.

[32]  F. Colpaert,et al.  Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice , 1996, Brain Research.

[33]  J. Beckman.  Oxidative damage and tyrosine nitration from peroxynitrite. , 1996, Chemical research in toxicology.

[34]  E. Schömig,et al.  The Extraneuronal Transporter for Monoamine Transmitters Exists in Cells Derived from Human Central Nervous System Glia , 1996, The European journal of neuroscience.

[35]  A. Członkowska,et al.  Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[36]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[38]  Á. Almeida,et al.  Changes of Respiratory Chain Activity in Mitochondrial and Synaptosomal Fractions Isolated from the Gerbil Brain After Graded Ischaemia , 1995, Journal of neurochemistry.

[39]  A. Kupsch,et al.  Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. , 1995, Neuroreport.

[40]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[41]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[42]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[43]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[44]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[45]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[46]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  K. Tipton,et al.  Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.

[48]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[49]  D. Murphy,et al.  Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effects of MPP+. , 1992, Free radical biology & medicine.

[50]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[51]  D. Eisenberg,et al.  A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter , 1992, Cell.

[52]  J. Langston,et al.  MPTP‐Induced ATP Loss in Mouse Brain , 1992, Annals of the New York Academy of Sciences.

[53]  B. A. Brooks,et al.  Midbrain Dopaminergic Cell Loss in Parkinson's Disease and MPTP‐Induced Parkinsonism: Sparing of Calbindin‐D25k—Containing Cells a , 1992, Annals of the New York Academy of Sciences.

[54]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[55]  S. Markey,et al.  Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease , 1992, Brain Research.

[56]  J. Cooper,et al.  Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.

[57]  H. Przuntek,et al.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. , 1991, European journal of pharmacology.

[58]  B. Freeman,et al.  Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. , 1991, Archives of biochemistry and biophysics.

[59]  J. Langston,et al.  Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. , 1991, The Journal of pharmacology and experimental therapeutics.

[60]  J. Langston,et al.  Rapid ATP Loss Caused by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mouse Brain , 1991, Journal of neurochemistry.

[61]  D. A. Monte.  Mitochondrial DNA and Parkinson's disease , 1991 .

[62]  J. Casida,et al.  Interaction of 1‐Methyl‐4‐Phenylpyridinium Ion (MPP+) and Its Analogs with the Rotenone/Piericidin Binding Site of NADH Dehydrogenase , 1991, Journal of neurochemistry.

[63]  B. Westerink,et al.  Acute effects of intranigral application of MPP+ on nigral and bilateral striatal release of dopamine simultaneously recorded by microdialysis , 1991, Brain Research.

[64]  H. Bergman,et al.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.

[65]  Z. Rossetti,et al.  The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+) , 1990, Neuroscience Letters.

[66]  T. Hattori,et al.  Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death , 1990, Brain Research.

[67]  B. Freeman,et al.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[68]  T. Murphy,et al.  Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress , 1989, Neuron.

[69]  K Mizukawa,et al.  Anatomy and Pathology of the Basal Ganglia , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[70]  Y. Mizuno,et al.  Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. , 1987, Biochemical and biophysical research communications.

[71]  J. Langston,et al.  Older dopaminergic neurons do not recover from the effects of MPTP , 1987, Neuropharmacology.

[72]  B. Halliwell,et al.  Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Identification of hydroxylated derivatives of salicylate in human body fluids. , 1986, The Biochemical journal.

[73]  R. M. Rose,et al.  Distinct monoamine oxidase A and B populations in primate brain. , 1985, Science.

[74]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[75]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[76]  K. Chiba,et al.  Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. , 1985, Biochemical and biophysical research communications.

[77]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[78]  R. Floyd,et al.  Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. , 1984, Journal of biochemical and biophysical methods.

[79]  M. Yahr,et al.  Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. , 1984, European journal of pharmacology.

[80]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[81]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[82]  A. Sahgal,et al.  N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat , 1984, Neuroscience Letters.

[83]  C. Marsden,et al.  Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. , 1984, Biochemical pharmacology.

[84]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[85]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[86]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[87]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[88]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[89]  P. Riederer,et al.  Neurotransmitters and Disorders of the Basal Ganglia , 1999 .

[90]  G. Kite,et al.  Environmental MPTP as a factor in the aetiology of Parkinson's disease? , 1998, Journal of Neural Transmission.

[91]  S. Padmaja,et al.  The reaction of no with superoxide. , 1993, Free radical research communications.

[92]  L. Karam,et al.  Biomarkers of OH radical damage in vivo. , 1991, Free radical research communications.

[93]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.

[94]  C. Marsden,et al.  MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects. , 1987, Advances in neurology.